Holen Sie sich die Stockscreener-App
11.81
0.08%
-0.010
Schlusskurs vom Vortag:
$11.82
Offen:
$10.86
24-Stunden-Volumen:
64,279
Relative Volume:
1.12
Marktkapitalisierung:
$82.94M
Einnahmen:
$100.44M
Nettoeinkommen (Verlust:
$-133.16M
KGV:
-0.4585
EPS:
-25.76
Netto-Cashflow:
$-94.85M
1W Leistung:
-20.47%
1M Leistung:
-24.44%
6M Leistung:
+62.67%
1J Leistung:
+16.93%
1-Tages-Spanne:
$10.53
$12.04
1-Wochen-Bereich:
$10.50
$15.30
52-Wochen-Spanne:
$5.005
$18.70
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Vergleichen Sie ATRA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
11.81 | 83.01M | 100.44M | -133.16M | -94.85M | -25.76 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Will Atara Biotherapeutics Inc. (AT20) stock beat value stocksMarket Volume Summary & Low Risk Profit Maximizing Plans - newser.com
Can Atara Biotherapeutics Inc. stock deliver sustainable ROEJuly 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
Atara Biotherapeutics Inc expected to post a loss of 86 cents a shareEarnings Preview - TradingView
Can machine learning forecast Atara Biotherapeutics Inc. recoveryQuarterly Profit Review & AI Powered Market Entry Ideas - newser.com
Atara Biotherapeutics (ATRA) Surges 10.0%: Is This an Indication of Further Gains? - Yahoo Finance
Live market analysis of Atara Biotherapeutics Inc.Quarterly Trade Summary & Precise Swing Trade Alerts - newser.com
How robust is Atara Biotherapeutics Inc. (AT20) stock financial positionTrade Volume Report & Risk Controlled Daily Plans - newser.com
Will Atara Biotherapeutics Inc. stock maintain growth storyMarket Performance Report & Low Drawdown Momentum Trade Ideas - newser.com
How Atara Biotherapeutics Inc. (AT20) stock performs during market turbulenceMarket Performance Report & Daily Entry Point Alerts - newser.com
How Atara Biotherapeutics Inc. stock compares to market leadersEarnings Trend Report & Verified Entry Point Detection - fcp.pa.gov.br
Is Atara Biotherapeutics Inc. (AT20) stock nearing a technical breakoutBear Alert & Safe Capital Growth Tips - newser.com
Custom strategy builders for tracking Atara Biotherapeutics Inc.Weekly Investment Report & Technical Confirmation Alerts - newser.com
Energy Moves: Will Atara Biotherapeutics Inc. (AT20) stock beat value stocksJuly 2025 Short Interest & Smart Allocation Stock Reports - fcp.pa.gov.br
Is Atara Biotherapeutics Inc. (AT20) stock trading at attractive multiplesEarnings Beat & Reliable Price Breakout Signals - newser.com
Institutional scanner results for Atara Biotherapeutics Inc.Quarterly Profit Review & Step-by-Step Swing Trade Plans - newser.com
Will Atara Biotherapeutics Inc. (AT20) stock sustain uptrend momentumCPI Data & Stepwise Swing Trade Plans - newser.com
How Atara Biotherapeutics Inc. stock benefits from strong dollarEarnings Risk Summary & Free Expert Verified Stock Movement Alerts - fcp.pa.gov.br
Atara Biotherapeutics (ATRA) to Release Earnings on Tuesday - MarketBeat
Is Atara Biotherapeutics Inc. stock supported by strong fundamentalsJuly 2025 Catalysts & Weekly High Momentum Picks - newser.com
How to recover losses in Atara Biotherapeutics Inc. stockJuly 2025 Intraday Action & Community Consensus Stock Picks - newser.com
Pierre Fabre takes over tabelecleucel BLA from Atara Biotherapeutics By Investing.com - Investing.com Australia
Pullback Watch: Can Atara Biotherapeutics Inc. stock attract ESG capital inflowsStop Loss & Consistent Income Trade Recommendations - fcp.pa.gov.br
Atara Biotherapeutics (ATRA) Transfers Key FDA Application to Pi - GuruFocus
Pierre Fabre takes over tabelecleucel BLA from Atara Biotherapeutics - Investing.com
Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - Barchart.com
Will Atara Biotherapeutics Inc. stock attract ESG investorsJuly 2025 Reactions & Short-Term High Return Strategies - newser.com
Will a bounce in Atara Biotherapeutics Inc. offer an exitWall Street Watch & Expert Verified Stock Movement Alerts - newser.com
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Aug 18 '25 |
Sale |
11.61 |
1,809 |
21,009 |
35,258 |
| Panacea Innovation Ltd | 10% Owner |
Aug 15 '25 |
Buy |
12.19 |
55,000 |
670,422 |
1,405,000 |
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):